Paul R. Kirchgraber - Feb 2, 2023 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role
CEO, Covance Drug Development
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Stock symbol
LH
Transactions as of
Feb 2, 2023
Transactions value $
-$35,954
Form type
4
Date filed
2/6/2023, 02:45 PM
Previous filing
Nov 3, 2022
Next filing
Feb 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LH Common Stock Options Exercise +443 +3.4% 13.5K Feb 2, 2023 Direct F1
transaction LH Common Stock Tax liability -$36K -141 -1.05% $254.99 13.3K Feb 2, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LH Restricted Stock Unit Options Exercise $0 -443 -15.29% $0.00 2.45K Feb 2, 2023 Common Stock 443 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2 Stock withholding to satisfy tax withholding obligations.
F3 The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022.
F4 This number reflects the aggregate number of Restricted Stock Units held by the reporting person.